Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide.
I. Introduction
Second to Alzheimer's disease (AD), Parkinson's disease (PD) is the most common neurodegenerative disorder worldwide. As PD risk increases with age, the incidence of this devastating and debilitating condition is predicted to have increased a further 50% by 2030 (Dorsey et al., 2007; Tanner and Goldman, 1996) . Clinically, PD is characterized by classical motor deficits that result from loss of dopaminergic neurons in the substantia nigra (SN) pars compacta (SNPC). A range of other symptoms that occur in the course of PD reflects disturbances in other brain regions and/or neurotransmitter systems (Kalia and Lang, 2015) .
Furthermore, the incidence of dementia in PD is several-fold higher than in age-matched controls (Hely et al., 2008) . Apart from the loss of dopaminergic neurons in the SNPC, alphasynuclein pathology is the neuropathological hallmark of PD. It consists of proteinaceous inclusions enriched in filamentous forms of α-synuclein and other proteins in the cell bodies (Lewy bodies) and processes of neurons (Lewy neurites) (Abeliovich and Gitler, 2016; Spillantini et al., 1997) . Clues about the etiology of PD have been garnered via pathological, genetic and epidemiological studies and several environmental and genetic risk factors have been identified (Abeliovich and Gitler, 2016; Kalia and Lang, 2015) . Converging genetic evidence supports defects in endosomal trafficking, protein disposal via the proteasome and/or lysosome-autophagy system and mitochondrial function (International Parkinson Disease Genomics et al., 2011; Nalls et al., 2014) .
Like PD, Lewy body dementia (LBD) is characterized by Lewy body pathology in limbic and cortical structures. However, progressive cognitive impairment, visual hallucinations and fluctuations of attention occur prior to or within one year of Parkinsonian motor symptoms in LBD, while the interval between motor symptoms and cognitive impairment is typically much longer in PD dementia (McKeith et al., 2005) .
A C C E P T E D M A N U S C R I P T
Peroxisome proliferator activated receptor gamma coactivator 1α (PGC-1α), encoded by PPARGC1A, is a transcriptional co-activator that integrates transcriptional programs that are relevant in the pathogenesis of neurodegenerative disorders and include mitochondrial biogenesis and function, the defense against reactive oxygen species and autophagy (Handschin and Spiegelman, 2006; Lin et al., 2005; Lin and Beal, 2006; Soyal et al., 2006; Tsunemi et al., 2012) . Indeed, associations of the PPARGC1A locus with Huntington disease and amyotrophic lateral sclerosis have been reported previously (Eschbach et al., 2013; Soyal et al., 2012; Weydt et al., 2009 ). The first indication for a role of PGC-1α in PD came from studies in PGC-1α knock-out mice that demonstrated enhanced sensitivity to the oxidative stressor 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (St-Pierre et al., 2006) .
MPTP-induced degeneration of dopaminergic neurons was prevented by PGC-1α (Mudo et al., 2012) . Furthermore, silencing of PGC-1α increased the susceptibility of SH-SY5Y cells to N-methyl-4-phenylpyridinium ions and inhibited mitochondrial function (Ye et al., 2017) Overexpression of PGC-1α prevented cell death of embryonic rat midbrain cells transduced with A53T -synuclein-encoding adenovirus (Zheng et al., 2010) . Moreover, progressive
Parkinsonism was observed in mice with conditional disruption of the PGC-1α target gene TFAM (Ekstrand et al., 2007) . In 3D5 cells conditionally overexpressing α-synuclein, knockdown of PGC-1α increased α-synuclein oligomers/aggregates and decreased levels of AKT, GSK3β and p53 (Ebrahim et al., 2010) and α-synuclein toxicity can be reduced by pharmacological activation or overexpression of PGC-1α (Eschbach et al., 2015) . In addition, α-synuclein was shown to bind to the PGC-1α promoter in brain tissue and reduced promoter activity of PGC-1α and its target gene expression in vitro (Siddiqui et al., 2012) .
We recently discovered multiple new PPARGC1A transcripts that initiate from a novel promoter located 587 kb upstream of exon 2 (Soyal et al., 2012) . We showed that these new transcripts are CNS-specific, are more abundant than the reference gene (RG) transcripts in whole brain and are partially conserved in rodents. Two main transcripts with independent ACCEPTED MANUSCRIPT
6 methionine start codons encode full-length CNS-isoforms that differ only at their N-termini from PGC-1α encoded by the RG. Truncated isoforms containing these N-termini exist that are similar to NT-PGC-1α (Zhang et al., 2009) or are encoded by transcripts harboring a stop codon in an extended exon 3 resulting in 17 kDa proteins. The new CNS-promoter lies in a haplotype block clearly separated from the RG promoter, is active in SH-SY5Y and NTERA2cl.D1 (NT2/D1) cells and is located within a CpG island. The structure of the CNS transcripts, their CNS-specific expression and their higher expression levels in comparison to RG transcripts has now been confirmed in independent studies (Jiang et al., 2016; Wang et al., 2016) .
In most previous studies on PGC-1α and PD, only the RG (Esterbauer et al., 1999) (GenBank NM_013261.3) was addressed and very little is known about the more abundant CNS-specific transcripts/isoforms. We therefore determined levels of various transcripts and proteins encoded by the PPARGC1A locus in several regions of post-mortem brain tissues from neuro-pathologically verified PD and LBD cases and controls. Similar measurements were also made in animal models of PD. Furthermore, the CNS-specific PPARGC1A genomic region was interrogated for possible associations with PD.
Materials and methods

Post-mortem human resources
Human brain tissue and DNA samples were procured from the brain bank of the Department of Neuropathology, Kepler University Hospital, Linz, Austria. Following federal law, postmortem tissue can be removed by autopsy for diagnostic or scientific purposes. Upon removal, the brain was separated into the two hemispheres by a mid-sagittal cut which also allows hemi-dissection of the cerebellum and the brain stem. One half of the brain was
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The second half of the brain was fresh frozen at -80° C as follows: The brainstem with the cerebellum was dissected at the level of the pons and midbrain. A slice containing the substantia nigra and nucleus ruber was generated and frozen. The cerebellum was removed from the brainstem by a cut though the cerebellar peduncles. The brainstem was cut into thin slabs perpendicular to its main axis. Slices of the cerebellum were generated parallel to the vermis. The cerebral hemisphere was cut into 1 cm thick coronal slabs and frozen. After thorough gross-anatomical examination of the fixed hemisphere, 20 tissue blocks were cut for histopathological examination. For each block the following staining was performed:
Hematoxylin and eosin, Luxol Fast Blue, immunohistochemistry for beta A4 amyloid, tau, phosphorylated tau, tau 3 repeat, tau 4 repeat, α-synuclein, ubiquitin, p62, TDP-43 and FUS.
PD related pathology was graded according to Braak et al. in stages 1-6, i.e. medulla oblongata (stage 1), medulla oblongata and pontine tegmentum (stage 2), midbrain (stage 3), basal prosencephalon and mesocortex (stage 4), high order sensory association areas of the neocortex (stage 5) and first order sensory association areas of the neocortex (stage 6) (Braak et al., 2003) . For LBD, the lesions were typed according to the following criteria: brainstem predominant (type 1), limbic transitional (type 2) and diffuse neocortical (type 3) (McKeith et al., 2005) . All examined cases were of the diffuse neocortical type. The topographical localization of neurofibrillary tangles was staged according to Braak & Braak E: transentorhinal cortex (stage I-II), limbic (stage III-IV) and isocortical (stage V-VI) (Braak and Braak, 1991) .
Frozen tissue samples were removed with a special trepan (diameter 4 mm) from the frontal lobe, SNPC, globus pallidus, parietal lobe and cerebellum of 21 and 8 deceased subjects with idiopathic PD and LBD, respectively. Tissue samples from 13 subjects who died after age 50 without neurodegenerative disorders with the exception of minor AD neuropathology, but no signs of clinical AD served as controls (Table 1 ). In addition, DNA
A C C E P T E D M A N U S C R I P T 8 samples from 169, 85 and 134 deceased subjects without neurodegenerative disorders, with PD or with AD, respectively, were used for genotyping.
Clinical resources
DNA from 196 subjects with PD and 206 subjects without neurodegenerative disorders from 415-EP/73/243-2013, Salzburg, Austria) and study subjects provided informed consent.
Animals
For measurements in the MPTP model, adult male and female C57BL/6J mice (Janvier), weighing 25-30 g, kept under standard conditions and housed in groups of 4 in individually ventilated cage systems to protect the experimenter from MPTP exposure, received four doses of 12.5 mg/kg MPTP in 2 hour intervals. Animals were sacrificed by neck dislocation before
and at 30 min, 1, 2, 3 and 7 days after the completed MPTP injection protocol. Brain tissues, obtained from the frontal lobe, the cerebellum, the midbrain including the SN and the striatum, were quickly dissected on ice and snap-frozen in liquid nitrogen. Tissue samples of the same brain regions of 7-8 month old transgenic mice expressing the human α-synuclein harboring the A30P mutation under the control of the mouse Thy-1 promoter (B6; D2-Tg (Th-1-SNCA*A30P) lin44) were also collected. All animal procedures were approved by the respective government agency (Animal Experiment 09-016, Presidential Office of the Government Tübingen, Baden Würtenberg, Germany).
Dopamine measurements
Brain samples were homogenized by ultrasonification for 10 s in 1 ml 0.4 M perchloric acid and centrifuged at 22,000 × g for 10 min at 4° C. Supernatants were passed through a 0.2 μm filter (Minisart RC4, Sartorius). Dopamine levels were determined by high-performance liquid chromatography using an electrochemical detector and isocratic conditions (Buck and Ferger, 2008) . The positions and areas of the peaks of the neurotransmitters of interest were compared with external standards using a standard calibration ranging from 10 −9 to 10 −6 M.
The neurotransmitter amounts were expressed as ng/mg wet tissue weight.
RNA and protein extraction
Total RNA from post-mortem human and mouse brain tissues was extracted using QIAzol lysis reagent and the RNeasy Lipid Tissue Mini Kit (QIAGEN). Frozen tissues (30-100 mg)
were placed into 2 ml tubes containing a 5 mm stainless steel bead, 700 -1000 µl QIAzol was added and tissue was homogenized using a TissueLyzer (QIAGEN) twice at 20 Hz for 3 min.
To obtain RNA and protein from the same sample, we used an optimized user-developed
protocol (QIAGEN-RY16). After the addition of 140-200 µl chloroform homogenates were centrifuged at 12,000 x g for 20 min at 4° C for phase separation. RNA was extracted from the upper aqueous layer using RNeasy spin columns according to the manufacturer's protocol.
RNA concentration and integrity was measured using a Nanovue Spectrophotometer (GE Healthcare) and the QIAxcel Advanced Instrument (QIAGEN), respectively. RNA integrity scores of <5 (two samples) were excluded. The remaining scores ranged between 5.0 and 6.8.
The phenol/ethanol supernatant containing the protein fraction was precipitated with 1.5 ml isopropanol, centrifuged at 12,000 x g for 10 min at 4° C and the supernatant removed.
The pellet was denatured with 2 ml guanidine-ethanol at room temperature for 20 min, centrifuged at 7,500 x g for 5 min and the supernatant removed. The latter step was repeated twice. After incubating with 2 ml of 100% ethanol for 20 min, pellets were air-dried and dissolved in 10 M urea containing 50 mM dithiothreitol at room temperature for 1 h followed by alternate steps of incubation at 95° C for 3 min and incubations on ice with periodic sonication (Sonoplus HB 27, Bandelin, Berlin), until proteins were completely dissolved.
After centrifugation at 10,000 x g for 10 min at room temperature, protein concentrations of the supernatants were determined using the Bradford assay (Bio-Rad).
Real-Time qPCR
DNase I-treated total RNA (1 µg/reaction) was reverse transcribed with the QuantiTect Reverse Transcription (RT) kit (QIAGEN), using a mix of random hexamer and oligo-dT primers as described (Auer et al., 2012) . cDNAs were amplified in duplicate by real-time PCR using Maxima SYBR Green (Thermo Scientific) or GoTaq qPCR Master Mix (Promega) and primers targeting exons B1 and B4 or B5 and exon 2, to quantify the two main CNS-specific PPARGC1A transcripts. RG transcripts were quantified using primers targeting exon 1 and exon 2. Primers targeting exon 5 and exon 7A or exon 2 and the extended part of Constitutively expressed RPLP0 (Ribosomal Protein, large, P0) RNA was used for normalization of mRNA abundance as described (Auer et al., 2012) . To determine the validity of RPLP0 as a reference gene, we also measured CYC1 mRNA levels, previously shown to be stably expressed in brain regions from PD and controls (Rydbirk et al., 2016) , in a subset of samples for comparison.
Plasmids
Plasmids used for in vitro transcription/translation included the coding sequences of the reference protein, B4-PGC-1α, B5-PGC-1α and the truncated isoforms NT-PGC-1α, B4-7a-PGC-1α, B5-7a-PGC-1α, E1-E3extended (ext), B4-E3ext and B5-E3ext cloned into the
BamHI/XhoI sites of the pT7CFE1-CHis vector (Thermo Scientific). Plasmids encoding the full length and NT transcripts were previously described (Soyal et al., 2012) . Plasmids encoding B5-PGC-1α-GFP, B4-7a-PGC-1α-GFP or PGC-1α7a-GFP (also termed NT-PGC-1α-GFP) used for immunocytochemistry have been described (Soyal et al., 2012) . Primers for the 3ext transcripts are listed in Supplementary Material, Table S1 . The human promoterluciferase reporter vectors pCD36Prom-Luc and pPCK1-Prom-Luc and the expression plasmids pHNF4α and pPPARγ were previously described (Felder et al., 2011) . The correct sequence was verified in all plasmids used.
In vitro transcription/translation
The 1-Step TM Human Coupled in vitro Transcription/Translation (IVT) Kit (Thermo Scientific) optimized for production of human proteins was used for synthesis of PGC-1α
proteins. Circular pT7CFE1-CHis plasmids (approximately 1 µg) containing the sequences encoding PGC-1α isoforms were incubated with 12.5 µl HeLa cell lysates, 2.5 µl accessory proteins and 5 µl reaction mix for 4 h 30 min at 30° C.
Immunoblotting and immunocytochemistry
In vitro transcription/translation products (4 µl reaction mixture) or proteins extracted from brain samples (40 µg) were denatured for 5 min at 95 o C in sample buffer (75 mM Tris-HCl, pH 6.8, 4% w/v SDS, 10% glycerol, 50 mM dithiothreitol, 0.01% w/v bromophenol blue), cooled on ice and subjected to electrophoresis in 7-10% polyacrylamide gels. Separated proteins were transferred to polyvinylidene fluoride membranes (Bio-Rad) that were blocked with 1x Tris-buffered saline (TBS), pH 7.6, containing 10% Blotting grade Blocker (Bio-Rad)
for 2 h at room temperature. Membranes were incubated with the primary antibodies, diluted Epitope-specific polyclonal antibodies were obtained to discriminate the various PGC-1α isoforms (Davids Biotechnology GmbH). Rabbits were immunized with MAWDMCNQDSESVWSDIE, MDETSPRLEEDWKKVLQREAGWQ and MDEGYF to obtain specific antibodies for the N-termini of the reference protein and the B5 or B4
isoforms, respectively. Antisera were affinity-purified using the respective peptides as ligands. Antibodies were tested using in vitro transcribed and translated products of clones encoding various isoforms and an in frame histidine-tag. The anti-exon 1 antibody correctly identified the translated full-length protein as well as NT-PGC-1α and E1E3ext, while isoforms initiated at B5 and B4 were not detected. The anti-B5 antibody identified all B5-initated isoforms, but failed to identify exon 1 and exon B4 initiated isoforms (Supplementary Material, Fig. S2 ). The anti-B4 antibody, directed against the very short B4-specific Nterminal sequence, failed to detect in vitro transcribed and translated isoforms. We used other peptides that contained the B4-specific epitope and extended into the coding region of exon 2 as antigens, but the antisera generated recognized a host of proteins. However, the initial anti- 
Cell culture and transfection experiments
SH-SY5Y cells were plated in 24-well dishes one day before transfection and transfected with plasmid constructs for 24-48 h using DNAfectin TM (ABM Inc.). pRL-TK plasmid (Promega) was used as transfection control. Luciferase activities were measured using the Dual Luciferase Reporter Assay System (Promega) as described (Oberkofler et al., 2002) . Results are means (SE) of three or more experiments, each performed in quadruplicate.
Genotyping
We typed rs17592631, rs11737023 and rs3966917, all localized in the brain-specific genomic PPARGC1A region, using TaqMan Genotyping Assays (Applied Biosystems). The respective typing reagents were C_32808047_10, C_473389_10 and C_26212324_10. The accuracy of typing was verified by sequencing of 10 alleles and repeat assays in 40 samples. In all cases, initial and repeat or sequence analyses showed identical results.
Statistical analysis
For comparison of categorical variables, we used a contingency χ 2 -test. For comparison of specific transcript levels by brain region and/or disease, one-or two-way ANOVA was used.
Logarithmic transformations were used if the equal variance and normality assumptions of ANOVA were rejected. Univariate associations were ascertained by linear correlation ACCEPTED MANUSCRIPT 
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Results
Studies in post-mortem human tissues
CNS-specific PPARGC1A transcripts are initiated in exon B1 followed by exons B4 and/or B5 and exon 2-exon 13 (Soyal et al., 2012 (Supplementary Material Fig. 1 ). RNA integrity scores showed no associations with age, sex, brain region, disease status or post-mortem time. Similarly, RPLP0 levels used for normalization of transcript levels revealed no associations with age, sex or post-mortem time.
However, two-way ANOVA using brain regions and control/PD/LPD status as independent Compared with B1B4 and B5E2 transcripts, E1E2 and E5E7A transcript levels differed by brain region to a lesser extent (P=0.0094 and P=0.0008), respectively. Post-hoc analysis revealed that E1E2 transcript levels were lower in the SNPC and cerebellum than in the frontal cortex, while E5E7A transcript levels were higher in cerebellum than in SNPC and globus pallidus. Region specific analyses showed no significant differences of the various PPARGC1A transcripts by disease status in frontal and parietal cortex, globus pallidus and cerebellum. However, lower levels of B1B4 (P=0.0055) and E5E7A (P=0.0480) and borderline lower levels of B5E2 (P<0.0753) and E1E2 (P=0.0711) of PD/LBD were observed
in the SNPC (Figure 1 , Table 2 ). No associations of PPARGC1A transcripts in the SNPC were noted with age, sex, RNA integrity or post-mortem time.
We have previously shown in mouse brain cells (by semiquantitative PCR) that the CNS-specific B4 containing transcripts are primarily expressed in neuronal cells and to a lesser extent in oligodendrocytes and microglia, but not, or only in minimal amounts in astrocytes. RG transcripts are expressed in astrocytes and neuronal cells and to a lesser extent in oligodendrocytes and microglia (Soyal et al., 2012) . Hence, differences in transcript levels between controls and PD or LBD cases may result from changes in the cellular composition of tissue samples. Therefore, we measured mRNA levels of marker genes for astrocytes (GFAP), microglia (AIF), neurons (ENO2, MAP2) and dopaminergic neurons (TH) ( Table 2 ).
Levels of GFAP and AIF transcripts did not change with disease status in the SNPC, but transcript levels of TH, MAP2 and ENO2 were substantially reduced in PD and LBD cases. In going from controls to PD and/or LBD, transcript ratios of B1B4 to GFAP decreased (P<0.05), while ratios of B1B4 to AIF and ENO2 did not change significantly. However, transcript ratios of B1B4 to TH or MAP2 even increased (P<0.05). These results are consistent with a predominant loss of dopaminergic neuronal cells in SNPC.
For studies on isoform expression, we used epitope-specific polyclonal antibodies, termed anti-E1, -B4 and -B5 and directed against the N termini of the reference PGC-1α and the CNS-specific isoforms with translation start codons in exon B4 and B5, respectively. In
Western blots of protein extracts from the regions collected (Supplementary Material, Fig.   S4 ), we noted differences in the intensities of bands by brain regions, but the antibodyspecific protein patterns were similar among regions. We next analyzed the protein patterns in SNPC and globus pallidus from 14 PD and 9 control cases (Fig. 2) . Again, we observed considerable variability in levels of protein isoforms in both PD and control. Generally, PGC-1α proteins were expressed at higher levels in SNPC than in globus pallidus. Although the sizes of the proteins detected by the three antibodies were in some cases similar considering Table S2 ), not all bands that were strongly reduced in preincubation experiments with the respective immunization peptides could be clearly assigned to their transcript structure. For instance, the 55 kDa protein harboring the B4-epitope has recently been suggested to be non-specific (Ruas et al., 2012) . However, this protein was selectively recognized by the anti-B4 antibody and may be encoded by RNA species with apparent sizes of 3.2 or 2.8 kb that we have detected in Northern blots of human brain RNA with probes consisting of CNS-specific exons B2-B5 and exons 2-7 (Soyal et al., Fig. 3A ). Proteins with sizes expected for full-length reference, B4 and B5 proteins were also detected, but they were less abundant than the truncated isoforms. Proteolysis appeared to reduce the levels of some proteins, as post-mortem time was inversely associated with abundance levels of proteins detected with the anti-B5 antibody including the 100 kDa (p=0.001), the 82 kDa (P=0.023) and the 63 kDa (p=0.035). Associations of post-mortem time with proteins detected with the anti-E1 and anti-B4 antibodies were not observed. Compared to controls, PD cases showed a greater abundance levels of B4-30 and B4-17 kDa proteins in the globus pallidus (P<0.05). A similar trend for the B4-17 kDa protein was noted in SNPC (P<0.07), while B4-30 kDa proteins were detected in the SNPC only in few cases. To substantiate these results, we measured E2E3ext transcripts likely to encode the 17 kDa isoform and observed higher levels in PD in comparison to controls in SNPC (P=0.008) and globus pallidus (P=0.035) (Fig. 3) .
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No associations of E2E3ext transcript or 17 kDa isoprotein levels in SNPC or globus pallidus with age, sex, post-mortem time or RNA integrity were observed.
As the B4-17 kDa protein may represent an inhibitory isoform, we performed transient co-transfection studies in SHSY-5Y cells using the PCK1 or the CD36 promoter reporter plasmids along with expression vectors encoding HNF4α or PPARγ (Fig. 4) . Plasmids encoding full-length PGC-1α isoforms with or without pB4-PGC-1α-3ext were cotransfected. PGC-1α was a stronger co-activator of HNF4α on the on the PCK1 promoter in comparison to B5-PGC-1α, while no differences between the three full-length proteins were observed in PPARγ coactivation of the CD36 promoter. The truncated B4-E3ext protein inhibited the co-activation of all three full-length proteins on both promoters in a dose dependent fashion.
Animal studies
Our previous studies described the presence of B1b4 containing Ppargc1a transcripts in the CNS of mice (Soyal et al., 2012) and rats (unpublished). B5e2 transcripts were not detected in mice and such transcripts would have a very short open reading frame of 11 amino acid residues. Tissue samples from brain regions of the MPTP mouse model were collected before and 30 min, 1, 2, 3 and 7 days after completion of the MPTP injection schedule. The MPTP treatment resulted in the expected dopamine decrease in the striatum and a surge in striatal Tnfα mRNA levels 24 h after the last dose (Fig. 5) . Two-way analyses of transcript data revealed significant effects of time for both B1b4 (P<0.0001) and E1e2 (P=0.0055)
transcripts, but the effect of region was only significant for B1b4 (P=0.0001). Analyses in individual brain regions showed significant decreases of B1b4 and E1e2 transcripts in all regions by time. Transcripts encoding the inhibitory 17 kDa isoform were detected only at very low levels. Eno2 transcript levels measured in midbrain, frontal cortex and striatum also We next analyzed the transcript levels in genetically modified mice in which the human α-synuclein gene harboring the A30P mutation is expressed under the control of the mouse Thy-1 promoter (B6;D2-Tg(Thy1-1-SNCA*A30P)lin44). In comparison to wild-type mice, the transgenic mice displayed lower B1b4 transcript levels in midbrain and striatum (both P<0.05), while E1e2 transcripts were markedly reduced in all four sampled regions, in particular, in the striatum (Fig. 6 ).
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Genetic studies
To determine potential associations of the CNS-specific genomic region of PPARGC1A, we typed rs17592631, rs11737023 and rs3966917, all located far upstream of the RG promoter, in a cohort of PD and subjects without neurodegenerative disorders from the South Tyrolean region. To increase power, we typed participants from the SAPHIR study free of neurodegenerative diseases (Supplementary Material, Table S2 ). Table S5 ).
Discussion
Studies in mice have shown that adult conditional knockout of exon 3-5 of Ppargc1a, which targets reference as well as all B4-containing CNS-specific isoforms, leads to loss of dopaminergic neurons in the SNPC and robust amphetamine-induced ipsilateral rotation (Jiang et al., 2016) . Similar results have been demonstrated in rats (Zheng et al., 2017) . Upper vertebrates have an expanded repertoire of CNS-transcripts (including B5 containing transcripts) that are not expressed in mice or rats and may allow for a more finely tuned neuronal survival program in response to stress. Our human post-mortem studies extend previous studies by including the main encoding transcripts and show marked differences in the distribution of the CNS-specific transcripts B1B4 and B5E2 among the brain regions analyzed, while the distribution of RG transcripts is much less influenced by region.
Intriguingly, the lowest levels of CNS-transcripts were noted in globus pallidus and SNPC
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23 thought to be very sensitive to toxic insults and/or energetic defects (Obeso et al., 2017) .
Significant or borderline reductions in the SNPC were noted for B1B4 and E5E7A or B5E2
and E1E2 transcripts, respectively, while changes of any of the transcripts in other brain regions were not significant. Reduced levels of PPARGC1A transcripts in SNPC were reported recently in PD without details about the targeted gene regions (Su et al., 2015) .
Another study reported reduced levels of E1E2 and B1B4 transcripts in PD (Eschbach et al., 2015) . Similar to the latter study, the variability of transcript levels was large and may not only result from inter-individual variability, disease heterogeneity and tissue sampling, but pre-terminal insults such as hypoxia,, as we have experimental evidence for differences in the regulation of transcription from the CNS and RG promoters by various signaling pathways including hypoxia (Soyal SM and Patsch W, unpublished) . As our study was performed in SNPC tissue and neuronal markers were substantially decreased, the reduction of CNSspecific transcripts in PD and LBD may result simply from a loss of dopaminergic neurons that express them and modest changes in promoter regulation. Nevertheless, the data in mice
show that these transcripts may be themselves required for dopaminergic neuronal survival.
As Lewy bodies were required for the PD diagnosis in our study, forms of PD that are not necessarily associated with Lewy bodies (Doherty et al., 2013; may have different PPARGC1A expression profiles. For instance, in Parkin-associated PD, PARIS, a substrate for the E3 ubiquitin ligase Parkin, accumulates, represses transcription from the PGC-1α promoter and causes selective loss of dopaminergic neurons in the SN that can be abrogated by overexpression of PGC-1α (Shin et al., 2011) .
The reductions in specific PPARGC1A transcripts and transcripts of cell-specific markers tended to be more pronounced in LBD in comparison to PD, but only MAP2 and ENO2 transcripts were significantly lower in LBD. These results are in keeping with strong overlaps in the clinical picture and neuropathology of LBD and PD and the view, that these
24 disorders may reflect specific entities of a continuous disease spectrum termed alphasynucleinopathies (Lippa et al., 2007) .
The analyses of proteins revealed multiple bands with differences between the antibodies used. Not all bands could be clearly assigned to the transcript structures that have been identified so far. Post-mortem degradation of proteins may have contributed to low levels of some proteins. It is also possible that other proteins contained epitopes used for generation of antisera. Hence, we can not exclude that some proteins identified by competition assays are not PGC-1a isoforms. However, using the eukaryotic gene prediction tool Gnomon (http://wwwncbinlmnihgov/RefSeq/Gnomon-descriptionpdf), additional new B5-initiated isoforms have been predicted from the human genomic sequence that are supported by mRNA and EST evidence in the NCBI database (entries XP_011512071, XP_005248191) and have predicted MW of 77.2 and 79.8 kDa. Furthermore, multiple bands have been detected in neuronal cell lines with other antibodies directed against the N-terminal region of PGC-1α (Hasegawa et al., 2016; Ye et al., 2017; Ye et al., 2016 ).
An exciting and potentially important result was the PD-associated increase of the 17 kDa bands detected with the anti-B4 antibody and likely representing the translation product of B4-E3ext transcripts. A similar protein initiated at an alternative transcription site has been reported in another study (http://scholarscompass.vcu.edu/etd/3225/). The respective protein lacks the second LXXLL motif that serves as an interaction site for several nuclear receptors including HNF4α. The truncated proteins also lack nuclear localization signals, but their size <20 kDa should not impede their diffusion through the nuclear pore complex (Cyert, 2001 ).
Indeed, we show now that the B4-PGC1-α3ext inhibits the co-activation of several promoters by full-length CNS-specific and reference proteins.. As co-activation of PPARγ whose interaction site has been mapped distal to the second LXXL motif was also inhibited, heterodimerization and/or competition of truncated and full-length proteins for factors that enhance the co-activation properties of PGC-1α such as SRC-1 and p300 are likely modes of
inhibition (Puigserver et al., 1999) . A genome-wide expression study conducted in part in laser-captured dopaminergic neurons found that a set of 425 PGC-1α-responsive genes was significantly under-expressed in PD (Zheng et al., 2010) . Two other studies using laser microdissection reported no significant reduction of PPARGC1A transcripts or PGC-1α immunoreactivity in substantia nigra neurons (Dolle et al., 2016; Simunovic et al., 2009 ).
Thus, in sum these studies would suggest that the transcriptional function of PGC-1α is compromised in idiopathic PD despite moderated, if any reductions in its expression. It is therefore conceivable that the 17 kDa protein may contribute to the functional impairment observed in PD. However, additional studies are required to support the hypothesis that such a mechanism contributes to the pathogenesis of PD.
Full-length CNS-and RG-PGC-1α displayed subtle differences in co-activation of HNF4α at the PCK1, but not of PPARγ at the CD36 promoter. Previous studies showed that alternative PGC-1α isoforms display distinct transcriptional regulation and protein stability.
The N-terminal activation and repression domains, but not the RS/RNA recognition motifs appeared to determine gene programs as well as splicing events that are specifically regulated by some isoforms (Martinez-Redondo et al., 2016) . Furthermore, an interaction of Necdin with the N-terminal region resulted in increased stabilization of PGC-1α and enhanced mitochondrial function in primary neurons (Hasegawa et al., 2016) . Whether the CNSspecific isoforms that possess distinct N-termini differ from the reference proteins in their transcriptional co-activation and splicing program, is currently under study.
The MPTP metabolite 1-methyl-4-phenylpyridinium induced Parkinsonism in young drug addicts (Langston et al., 1983) and has been identified as a complex 1 inhibitor (Cleeter et al., 1992) . Animal models based on MPTP intoxication have been used as valuable tools to study deficiencies in dopaminergic neurons, even though such models do not fully recapitulate human PD. Our studies in the acute MPTP model showed that dopamine levels decreased more rapidly and to a greater extent than TH mRNA levels. This finding is consistent with studies showing that the decrement in dopamine levels exceeds the loss of dopaminergic neurons in PD and that nitration of striatal TH that results in loss of enzymatic activity is induced by MPTP administration (Ara et al., 1998) . Like in human brain tissues, transcript levels of B1b4 in mice were more abundant than levels of E1e2 (Soyal et al., 2012; Szalardy et al., 2016) . Unlike in human post-mortem tissues, the decrease of B1b4 and E1e2 transcripts along with a decrease in Eno2 occurred in all brain regions studied suggesting a more general toxicity of the MPTP treatment in our animal model. Transgenic mice overexpressing the α-synuclein A30P mutation revealed moderately reduced mRNA levels of B1b4 and Eno2 transcripts in midbrain and striatum. However, reductions of E1e2 transcript levels were substantial in all brain regions, particularly in the striatum, and may result from down-regulation of the RG promoter activity by α-synuclein (Siddiqui et al., 2012) .
Our genetic studies showing consistent results in two populations suggest that the genomic region encompassing the CNS promoter and CNS-specific exons contributes to the pathogenesis of PD. Like in previous genome-wide association studies (GWAS), no associations of PD with individual SNPs were observed, but haplotypes typically are not reported in GWAS. The mechanisms whereby some haplotypes exhibit protective effects are not known, but may include the expression levels of specific isoforms in response to distinct signaling mechanisms. Importantly, some GWAS showed associations of the CNS-specific genomic region of PPARGC1A with phenotypes that are often encountered in PD. In subjects of European ancestry, a strong association of rs17590046, located between exons B1 and B4, with essential tremor (P-value<10 -9 ) was reported (Muller et al., 2016) and confirmed in an Asian population (Xiao et al., 2017) . Furthermore, a borderline significant association of rs16875528, also positioned between B1 and B4, with the sense of smell among US older adults (P-value=9.10 -6 ) was observed (Dong et al., 2015) . Our results must be cautiously interpreted, as a predicted, but not characterized locus lies in the same genomic region (LOC729175, NCB reference sequence XPP_001129558.1). Between amino acids 80-253,
the predicted protein contains a domain exhibiting homology to DNA polymerase gamma and tau. The hypothetical mRNA is transcribed from the same strand and in the same direction as the CNS-PPARGC1A transcripts. EST clones have been observed in ES cells (Genbank Nr.
CN283176) that overlap exon B1. We also observed similar transcripts in induced pluripotent stem cells and, to a lesser extent, in human brain tissue. Further characterization of LOC729175 is required, as variants of genes involved in mtDNA maintenance such as mtDNA polymerase gamma increase the risk of PD (Luoma et al., 2007) .
Conclusion
Taken together, a link between the CNS-specific PPARGC1A locus and idiopathic PD is 
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32 Tables   Table 1 Characteristics of post-mortem cases and controls Age of death 76 (11) 80 (7) 80 (7) n.s.
Post-mortem time, hrs 22 (20) 32 (20) 36 (38) n.s. PD, Parkinson's disease; LBD, Lewy body dementia; n.s., not significant; n.d., not determined Haplotype frequencies in controls and PD cases; ORs are relative to the most common haplotype; P=0.00301 for global haplotype effects in the combined sample. *1 or 2 refers to the major or minor alleles, respectively, in the following order: rs17592631 C/T; rs11737023 G/A and rs3966917A/G ACCEPTED MANUSCRIPT
43 Highlights  Post-mortem levels of recently discovered CNS-specific PPARGC1A transcripts encoding full-length proteins were reduced in the substantia nigra of Parkinson's disease (PD) cases  Levels of CNS-specific PPARGC1A transcripts encoding 17 kDa truncated isoforms were increased in the substantia nigra and globus pallidus of PD cases  In transfection assays, the 17 kDa proteins inhibited the co-activation of HNF4α and PPARγ at the PCK1 and CD36 promoters, respectively, by full-length PGC-1α isoforms  Specific haplotypes in the CNS-specific PPARGC1A genomic region protected against PD in two populations with comparable geographic and ethnic backgrounds
